Okyo Pharma announces its drug candidate OK-101 demonstrates potential for treating dry eye disease
December 14, 2021
According to the company, OK-101 displays both anti-inflammatory and ocular pain-reducing potential.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Dry Eye
Aramis Biosciences announces FDA clearance of IND application for A197
January 13, 2022
According to the company, A197 is a novel, first-in-class, topical immunomodulatory agent which will move into Phase II clinical trials in dry eye patients.
Rethinking dry eye disease with acute steroid treatment
December 13, 2021
According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation
Promising results from phase 2b study of AR-15512 for the treatment of dry eye
December 13, 2021
At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.
I-MED Pharma USA gains distribution rights for ESW Vision’s dry eye devices
December 09, 2021
I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.
Dry eye severity, treatment varies among ethnic minority patients
December 08, 2021
Investigators are hopeful that future research can focus on public health concerns of dry eye disease.
Ocular Therapeutix announces topline results for phase 2 clinical trial of OTX-DED for short-term treatment of dry eye disease
December 06, 2021
Study shows statistically significant improvement for primary endpoint of bulbar conjunctival hyperemia for OTX-DED 0.2 mg and 0.3 mg formulations compared with vehicle hydrogel insert.
Varenicline nasal spray approved as a treatment for dry eye disease
November 17, 2021
Product stimulates basal tear production, restores tear film homeostasis, and relieves symptoms.
Clinical trial for treatment of dry eye disease clears Phase 2 hurdle
November 02, 2021
Aldeyra Therapeutics announced today that it has achieved the primary endpoint of ocular redness in its randomly assigned, double-masked, vehicle-controlled Phase 2 clinical trial in dry eye disease.
Oyster Point Pharma reports FDA approval of TYRVAYA nasal spray for DED treatment
October 18, 2021
Oyster Point Pharma, Inc. announced Monday that the U.S. FDA has granted approval of its TYRVAYA (varenicline solution) nasal spray 0.03 mg for the treatment of dry eye disease (DED), making it the first — and only — nasal spray approved for DED treatment in the U.S